Prosecution Insights
Last updated: August 18, 2026

Apellis Pharmaceuticals Inc.

6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Portfolio Summary

6
Total Pending OAs
5
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Due ≤ 30 days (2)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

6
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)6 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

60 h
Manual time on pending OAs
12 h
Time saved (low, 20%)
21 h
Time saved (mid, 35%)
0.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GARYU, LIANKO G 1 66.0% +45.3%
AEDER, SEAN E 1 56.9% +19.9%
HUMPHRIES, NICHOLAS ADAM 1 33.3% +78.6%
SABILA, MERCY HELLEN 1 57.6% +45.9%
HUDSON, AMY ROSE 1 75.0% +11.4%
HOWARD, ZACHARY C 1 63.8% +38.0%

Hard Cases (6)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18027331 METHODS OF TREATING EYE DISORDERS SABILA, MERCY HELLEN 22d
17798339 RNAS FOR COMPLEMENT INHIBITION HUDSON, AMY ROSE 26d
18386542 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS GARYU, LIANKO G 84d
18282664 POLYPEPTIDES FOR COMPLEMENT INHIBITION AEDER, SEAN E
18266464 GENOMIC EDITING OF COMPLEMENT HUMPHRIES, NICHOLAS ADAM
17791194 TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA HOWARD, ZACHARY C

Interview Candidates (6)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.

App #TitleExaminerDue in
18027331 METHODS OF TREATING EYE DISORDERS SABILA, MERCY HELLEN 22d
17798339 RNAS FOR COMPLEMENT INHIBITION HUDSON, AMY ROSE 26d
18386542 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS GARYU, LIANKO G 84d
18282664 POLYPEPTIDES FOR COMPLEMENT INHIBITION AEDER, SEAN E
18266464 GENOMIC EDITING OF COMPLEMENT HUMPHRIES, NICHOLAS ADAM
17791194 TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA HOWARD, ZACHARY C

Top Art Units

Art UnitApps
1654 2
1642 1
1631 1
1636 1
1674 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18386542 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS GARYU, LIANKO G 1654 §103§112Other Non-Final OA 84d Pending Nov 02, 2023
18282664 POLYPEPTIDES FOR COMPLEMENT INHIBITION AEDER, SEAN E 1642 §102§103§112 Non-Final OA Pending Sep 18, 2023
18266464 GENOMIC EDITING OF COMPLEMENT HUMPHRIES, NICHOLAS ADAM 1631 §103§112Other Non-Final OA Pending Jun 09, 2023
18027331 METHODS OF TREATING EYE DISORDERS SABILA, MERCY HELLEN 1654 §102§103§112 Non-Final OA 22d Pending Mar 20, 2023
17798339 RNAS FOR COMPLEMENT INHIBITION HUDSON, AMY ROSE 1636 §103§112 Final Rejection 26d Pending Aug 09, 2022
17791194 TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA HOWARD, ZACHARY C 1674 §102§103§112 Non-Final OA Pending Jul 06, 2022

Managing Apellis Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month